Artelo Posts Narrower Q2 Loss, Advances Pain Pipeline Toward Phase 1 MAD
ARTL is trading near its 52-week low of $0.705 (0.3% above the low) on light trading volume (0.1× avg).
Summary
Artelo reported Q2 2026 net loss of $2.4M ($0.89/share), narrowing from $3.2M a year ago, with cash of $4.2M. The company is preparing a Phase 1 multiple ascending dose study for lead asset ART26.12 in Q4 2026, supported by new nonclinical data showing pain relief comparable to naproxen with less gastric damage. Interim Phase 2 CAReS data for ART27.13 showed improvements in body weight and lean mass at the highest dose. This follows the 10-Q filed yesterday and the recent $11M financing; the pipeline progress is the key incremental news for a stock trading near its 52-week low.
At the time of this announcement, ARTL was trading at $0.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.6M. The 52-week trading range was $0.71 to $31.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.